ADVANZ PHARMA (CXRXF) Stock Price, News & Analysis

Company Overview

ADVANZ PHARMA (OTCMKTS:CXRXF) is a specialty pharmaceutical company focused on acquiring, developing and commercializing established and off-patent medications. The company’s portfolio spans a wide range of therapeutic areas including cardiovascular health, central nervous system disorders, pain management and women’s health. By targeting mature brands with established market demand, ADVANZ PHARMA seeks to extend product lifecycles and improve patient access to affordable treatments.

Formed in early 2021 through a series of strategic transactions led by private equity backer Advent International, ADVANZ PHARMA built its foundation on the acquisition of Alvogen’s legacy medicines portfolio. This initial aggregation of over 50 products set the stage for rapid geographic expansion. Since then, the company has continued to grow its range of generic and specialty prescription drugs through bolt-on acquisitions and internal development initiatives, reinforcing its position in Europe, Asia Pacific and select emerging markets.

In support of its global reach, ADVANZ PHARMA maintains manufacturing partnerships with contract facilities in India and Europe, ensuring consistent supply of high-quality medicines to more than 40 countries. The company’s operations encompass full lifecycle management—from regulatory filings and production oversight to marketing, distribution and patient support programs. By leveraging local commercial teams and third-party distributors, ADVANZ PHARMA adapts to diverse regulatory environments and healthcare systems.

ADVANZ PHARMA is led by a seasoned management team with deep expertise in pharmaceuticals and life sciences. The executive leadership brings prior experience from leading global companies such as Pfizer, Sandoz and Novartis. Its board of directors includes representatives from Advent International alongside independent members specializing in regulatory affairs, manufacturing and commercial strategy. This combination of financial backing and industry know-how underpins the company’s ongoing commitment to affordability, quality and sustained growth in the generic and specialty drug markets.

Key Stats

• Today's Range: $17.06 to $17.06
• 50-Day Range: $17.06 to $17.06
• 52-Week Range: $2.13 to $18.00
• Volume: 39 shs
• Average Volume: 11,851 shs
• Market Capitalization: $834.46 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CXRXF Stock Analysis - Frequently Asked Questions

How have CXRXF shares performed this year?

ADVANZ PHARMA's stock was trading at $17.06 at the beginning of 2025. Since then, CXRXF shares have increased by 0.0% and is now trading at $17.06.

How do I buy shares of ADVANZ PHARMA?

Shares of CXRXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:CXRXF
• CIK: N/A
• Web: www.advanzpharma.com
• Phone: 44-20-8588-9100
• Fax: N/A
• Employees: 429
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$74.86 million
• Net Margins: -15.31%
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -4.38%

Debt

• Debt-to-Equity Ratio: 257.04
• Current Ratio: 2.39
• Quick Ratio: 1.61

Sales & Book Value

• Annual Sales: $525.58 million
• Price / Sales: 1.59
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.16 per share
• Price / Book: 106.63

Miscellaneous

• Outstanding Shares: 48,913,000
• Free Float: N/A
• Market Cap: $834.46 million
• Optionable: Not Optionable
• Beta: N/A